Effectiveness of Virtual Reality Vision Therapy - VERVE

Launched by OCULOMOTOR TECHNOLOGIES · Dec 30, 2020

Keywords

ClinConnect Summary

The VERVE trial is studying how effective a new virtual reality treatment is for people with a condition called convergence insufficiency, which affects how well the eyes work together and can cause symptoms like eyestrain. In this trial, participants will use a virtual reality headset to play a specially designed video game that aims to improve their eye coordination and focusing abilities. The researchers will closely monitor eye movements during the game to objectively assess any changes in eye muscle responses and symptoms, without relying on participants to answer questions about their experience.

To participate in this study, individuals need to be at least 9 years old and have specific eye conditions, such as a certain score on a test related to eye strain. However, some people may not be eligible, including those with certain eye misalignments or medical conditions that could affect eye function. Participants can expect to engage in fun VR gameplay while helping researchers learn more about how this innovative approach might help improve vision-related issues for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 9 years and older
• • CISS score ≥ 16
• • Best-corrected distance visual acuity of 20/25 or better in each eye
• • Random dot stereopsis appreciation of 500 seconds of arc or better
• • Parent or subject understands the protocol and is willing to enroll in the study
• Exclusion Criteria:
• • Constant strabismus at distance or near
• • Vertical heterophoria ≥ 2 ∆ at distance or near
• • ≥ 2 line interocular difference in best-corrected visual acuity
• • Near point of accommodation \> 20 cm in either eye as measured by push-up method
• • Manifest or latent nystagmus
• • Non-strabismic binocular vision and accommodative disorders associated with known disease of the brain
• • Diseases known to affect accommodation, vergence, or ocular motility such as multiple sclerosis, Graves orbitopathy, myasthenia gravis, diabetes mellitus, Parkinson disease
• • Any ocular or systemic medication known to affect accommodation or vergence such as anti-anxiety agents (e.g., Librium or Valium), anti-arrhythmic agents (e.g., Cifenline, Cibenzoline), anti-cholinergics, bladder spasmolytic drugs (e.g., Propiverine), hydroxychloroquine, chloroquine, phenothiazines (e.g., Compazine, Mellaril, Thorazine), tricyclic antidepressants (e.g., Elavil, Nortriptyline, Tofranil)
• • Inability to comprehend and/or perform any study-related test or procedure